Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha variable 24 (TRAV24) is a specific variable gene segment encoding part of the variable region of the alpha chain in the T cell receptor (TCR) complex[1][3][9]. This region contributes to the antigen recognition capacity of TCRs expressed on T lymphocytes, enabling the adaptive immune system to detect peptides presented by major histocompatibility complex (MHC) molecules[1][2][4]. TRAV24, like other TCR variable gene segments, provides structural diversity to the antigen-binding site (mainly through the complementarity-determining regions, especially CDR1 and CDR3), shaping T cell specificity to foreign pathogens and altered self[2][8][9]. While TCR variable segments are not themselves direct drug targets, they are crucial as markers and potential engineering sites in T cell-based immunotherapies or diagnostic tools analyzing TCR repertoire diversity and clonal expansions[4][9].
Drugs/biologics targeting T cell receptors generally modulate antigen recognition and T cell activation via the specific variable region. No approved small molecules or direct drugs for TRAV24 specifically[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha variable 24 (TRAV24).